STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Ann Taber, Hospital Pharmacy, Aarhus University Hospital, Aarhus
  • ,
  • Youngrok Park, Georgetown University School of Medicine
  • ,
  • Alana Lelo, Georgetown University School of Medicine
  • ,
  • Frederik Prip
  • Jerry Xiao, Georgetown University School of Medicine
  • ,
  • Deborah L Berry, Georgetown University School of Medicine
  • ,
  • Krysta Chaldekas, Georgetown University School of Medicine
  • ,
  • Jørgen Bjerggaard Jensen
  • George Philips, Georgetown University School of Medicine
  • ,
  • Jung-Sik Kim, Georgetown University School of Medicine
  • ,
  • Brent T Harris, Georgetown University School of Medicine
  • ,
  • Lars Dyrskjøt
  • Todd Waldman, Georgetown University School of Medicine

OBJECTIVE: Improvements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC.

MATERIALS AND METHODS: STAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Cox proportional hazards models.

RESULTS: STAG2-negative low-grade NMIBC tumors were 2.5 times less likely to progress to muscle invasion than STAG2-positive low-grade NMIBC tumors (Log-rank test, P = 0.008). In a composite group of patients with AUA intermediate and high-risk NMIBC tumors, STAG2-negative tumors were less likely to progress (Log-rank test, P = 0.02). In contrast to NMIBC, we show that STAG2 is not useful as a prognostic biomarker in MIBC.

CONCLUSIONS: STAG2 immunostaining can be used to subdivide low-grade NMIBC tumors into two groups with substantially different risks of disease progression. Furthermore, STAG2 immunostaining may be useful to enhance NMIBC risk stratification guidelines, though larger cohorts are needed to solidify this conclusion in individual risk groups. STAG2 is not useful as a biomarker in MIBC. Further study of the use of STAG2 immunostaining as a biomarker for predicting the clinical behavior in NMIBC is warranted.

OriginalsprogEngelsk
TidsskriftUrologic Oncology: Seminars and Original Investigations
Vol/bind39
Nummer7
Sider (fra-til)438.e1-438.e9
ISSN1078-1439
DOI
StatusUdgivet - jul. 2021

Bibliografisk note

Copyright © 2021 Elsevier Inc. All rights reserved.

Se relationer på Aarhus Universitet Citationsformater

ID: 223143940